Table 1.

Patients with type 2 diabetes and chronic kidney disease, atherosclerotic cardiovascular disease, or heart failure on a sodium glucose cotransporter-2 inhibitor or glucagon-like peptide-1 receptor agonist [Information obtained from the Trend Report]

Location	Value	Pre-Intervention						Intervention				Post-Intervention
		June 30, 2020	Sept 30, 2020	Dec 31, 2020	March 31, 2021	June 30, 2021	Sept 30, 2021	Dec 31, 2021	March 31, 2022	June 30, 2022	Sept 30, 2022	Dec 31, 2022	March 31, 2023
VA nationally	Numerator	77,516	84,816	93,677	103,656	115,974	126,822	137,813	150,148	164,212	173,837	185,080	198,553
	Denominator	697,150	696,619	690,700	685,058	678,768	676,814	672,355	667,128	661,420	645,994	655,498	657,365
	Percentage	11.1	12.2	13.6	15.1	17.1	18.7	20.5	22.5	24.8	26.5	28.2	30.2
VISN 10 region	Numerator	8,056	8,864	9,663	10,806	11,996	13,068	14,248	15,417	16,616	16,605	17,606	18,707
	Denominator	66,525	66,614	65,726	64,985	64,594	64,337	63,839	63,035	61,847	58,525	58,061	58,041
	Percentage	12.1	13.3	14.7	16.6	18.6	20.3	22.3	24.5	26.9	28.4	30.3	32.2
VAAAHS	Numerator	934	1,048	1,148	1,347	1,549	1,665	2,038	2,308	2,603	2,797	2,883	3,086
	Denominator	7,081	7,394	7,169	7,267	7,272	7,336	7,318	7,191	7,369	7,374	7,258	7,275
	Percentage	13.2	14.2	16	18.5	21.3	22.7	27.9	32.1	35.3	37.9	39.7	42.4

Numerator: Number of Patients on SGLT2-i or GLP1-RA

Denominator: Number of Patients with T2DM with CKD, ASCVD, or HF

VAAAHS = Veterans Affairs Ann Arbor Healthcare System, VISN = Veterans Integrated Service Network